Matthew Li Kam Wa

🚨@REVIVED_BCIS2 scar analysis🫀 ➡️Scar volume & pattern highly associated with death and arrhythmia ➡️Scar assessment should be routine, particularly in those at borderline risk Out now @JACCJournals CVI🔗 jacc.org/doi/10.1016/j.… 📺Watch our summary👇 youtu.be/-eMrPRPToM0

This first randomized comparison of FFR & iFR in serial #cvCAD shows that both FFR & iFR pullbacks overestimate hemodynamic benefits of #PCI. Post-PCI physiology should be routinely performed in diffuse & serial disease. jacc.org/doi/10.1016/j.… @divaka_perera @mattlkw #JACCINT

Pressure-Derived Indices in Left Main Coronary Artery Disease @CircIntv ➡️ PW indices differ significantly between the LAD and LCx in isolated LMCA due to inherent differences in microvascular resistance and coronary flow. 🔗ahajournals.org/doi/10.1161/CI… @TheBHF @kingscardio

Cross talk not an issue as there was no pressure drop in the vessels beyond the LMCA. As close to normal epicardial conductance in LAD and LCx as virtually any reported data series. *btw we have some interesting data coming v soon on cross-talk doi.org/10.1186/ISRCTN… @mattlkw

🏴‍☠️CMD-HFpEF is a prevalent endotype of HFpEF ❌However, its pathophysiology remains incompletely understood ✅We discuss impaired lusitropy and subendocardial ischemia as the potential link between CMD and HFpEF bit.ly/3Pu66ro

What is the role of revascularisation for ischaemic heart failure after REVIVED? Look today in ICR3 for thoughts from REVIVED chief investigator @divaka_perera and NEJM editorial author @ajaykirtane. doi.org/10.15420/icr.2… #ICRJournal @UKheartresearch @REVIVED_BCIS2 @SabaAssar

Absolute pleasure to be invited to speak at #BCJACore2023, an event that I found so useful not that long ago (and pick up some cardio-oncology tips too)! Good luck to all those sitting the exam this year. @TheBJCA @hollymorgs @cfcamm

Universities 'finalising' a data sharing agreement ...

British Cardiovascular Intervention Society Jeopardy Score calculator launched #aci2023 today! BCIS-JS.com allows quick, reliable quantification of extent of coronary disease to assess trial eligibility and stratify clinical risk. @CHIP_BCIS3 @REVIVED_BCIS2 @BCIS_uk

Congratulations @DrMattRyan et al for their insightful work on invasive viability assessment doi.org/10.1161/CIRCIN…. NON-invasive viability assessment under the microscope when @divaka_perera presents the REVIVED Viability Analysis at Late Breaking Trials #ACC23 on Sat 4 March

Excellent review article discussing the different physiological phenotypes of CAD bit.ly/3tigOqd and re-iterating that serial CAD represents a diagnostic challenge in the catheter lab bit.ly/3WTo2hT @ColletCarlos @BernardBruyne @divaka_perera @DrBModi

There was no difference in the primary outcome at a median of 3.4 years, despite a high event rate in both arms.

In the 2nd row and the auditorium is packed. Apparently there is some trial being presented today? #ESCCongress @BlakeSarahR @hollymorgs @UKheartresearch @divaka_perera @REVIVED_BCIS2

Comparison of Flow Study (Doppler vs Thermo) ➡️CFR-thermo overestimates CFR-Doppler (modest correlation) ➡️Commonly used CFR-thermo threshold 2.0 has poor diagnostic accuracy ➡️Optimal CFR threshold 2.5 (thermo OR Doppler) 🔗jacc.org/doi/10.1016/j.… @JACCJournals #EuroPCR2022

In STEMI patients earlier treatment of non-culprit lesion during COVID‐19 pandemic associated with⬇️rates unplanned revascularization and myocardial infarction at 6⃣m f/u 🔗doi.org/10.1002/ccd.30… @LCC_DrMalik @divaka_perera @UKheartresearch @BCIS_uk @kingscardio @CCIJournal

Direct to cath lab or not after out of hospital cardiac arrest? A deep dive into COACT and TOMAHAWK here. #MedEd #CardioTwitter touchcardio.com/interventional… @DrNileshPareek @K_DeSilva @touchCARDIO @ukheartresearch @kingscardio

FLOWER-MI & root of the problem with non-culprit revascularisation @mattlkw @K_DeSilva @ColletCarlos @divaka_perera #OpenHeartBMJ #FLOWERMI bit.ly/3DQxRD7